What Makes hubXchange’s Roundtable Series Unique? Intimate, Senior-Level Roundtable Discussions: Engage with C-level ...

The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific ...

Specifically, that could include a ban on spread pricing – when a PBM reimburses pharmacies one price for a medicine, but ...

Its rare disease pipeline includes sickle cell disease therapy etavopivat, currently in the phase 2/3 HIBISCUS trial due to ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among ...

Mulvany – who left BenevolentAI when it listed on the Amsterdam stock exchange in 2022 and retains a sizeable stake in the ...